drug · antibody

OPDIVO QVANTIG

updated 3mo ago

by $BMY BRISTOL MYERS SQUIBB CO🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 8

Antibody drug with a maximum clinical stage of Approval (across all indications), with 15 approved and 112 investigational indications.

targets

Programmed cell death protein 1

all catalysts(0)

nothing on the calendar yet

Trials studying OPDIVO QVANTIG

phase2A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumorscompletedn=68
phase3Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutationsrecruitingn=400
phase2ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)active not recruitingn=66
phase1Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Studyrecruitingn=16
phase1NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomascompletedn=15
phase3Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)recruitingn=450
phase2A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)active not recruitingn=62
EP1A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancercompletedn=20

more trials →

News(10)

BMS picks Texas for new $2.3B manufacturing campus
Bristol Myers Squibb’s $2.3 billion Houston manufacturing campus is part of the company’s larger $40 billion investment designed to bolster American innovation and manufacturing.
biospace · 3d ago
Replimune rebounds to win FDA approval of melanoma drug
The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.
biopharma_dive · 7d ago
Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
Replimune’s immunotherapy for advanced melanoma faced a perilous regulatory road with two previous rejections, but the drug—to be marketed as Tudriqev—prevailed with strong support from oncologists…
biospace · 7d ago
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
The U.S. Food and Drug Administration today granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy for the treatment of advanced,…
fda_press · 7d ago
No deal between AstraZeneca and BMS, senior source insists: Reuters
Reuters has deflated rumors that AstraZeneca and Bristol Myers Squibb are discussing a possible merger, letting the air out of industry-wide speculation over what could have been the largest deal i…
biospace · 8d ago
Chaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad
The FDA has been trying to mend fences with rare disease drug developers and patient groups since the departure of former Commissioner Marty Makary three months ago. But advisory committee meetings…
biospace · 8d ago
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
The industry has been abuzz since the weekend when talks of a potential mega-merger between Bristol Myers Squibb and AstraZeneca were reported. Meanwhile, Pfizer, Merck and others release second qu…
biospace · 8d ago
As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
While both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be mo…
biospace · 9d ago
An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.
In fact, the former lost tens of billions of dollars in market value following reports of a potential tie-up between the pharmaceutical giants.
biopharma_dive · 10d ago
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
If AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.
biospace · 10d ago

view all news mentions →

brand

OPDIVO QVANTIG

trade names

Nivolumab bms, Nivolumab component of bms-986213, Nivolumab component of opdualag, Opdivo

generic

NIVOLUMAB

MOA

12.1 Mechanism of Action Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth. Hyaluronan is a polysaccharide found in the extracellular matrix of the subcutaneous tissue. It is depolymerized by the naturally occurring enzyme hyaluronidase. Unlike the stable structural components of the interstitial matrix, hyaluronan has a half-life of approximately 0.5 days. Hyaluronidase increases permeability of the subcutaneous tissue by temporarily depolymerizing hyaluronan. In the doses administered, hyaluronidase in OPDIVO QVANTIG acts transiently and locally. The effects of hyaluronidase are reversible and permeability of the subcutaneous tissue is restored within 24 to 48 hours.

indication

1 INDICATIONS AND USAGE OPDIVO QVANTIG is a combination of nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of: Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced RCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab. (1.1) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma. • adult patients with advanced RCC, as a first-line treatment in combination with cabozantinib. (1.1) • adult patients with advanced RCC who have received prior anti-angiogenic therapy. ( 1.1 ) Melanoma • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma. (1.2) • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma following combination treatment with intravenous nivolumab and ipilimumab. (1.2) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma. • for the adjuvant treatment of adult and pediatric (12 years and older who weigh 30 kg or greater) patients with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.3) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.4) • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by OPDIVO QVANTIG monotherapy as adjuvant treatment after surgery. (1.5) • adult patients with metastatic NSCLC and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor a

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 9m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · antibody

save

OPDIVO QVANTIG

updated 3mo ago

by $BMY BRISTOL MYERS SQUIBB CO🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 8

Antibody drug with a maximum clinical stage of Approval (across all indications), with 15 approved and 112 investigational indications.

targets

Programmed cell death protein 1

all catalysts(0)

nothing on the calendar yet

Trials studying OPDIVO QVANTIG

more trials →

News(10)

BMS picks Texas for new $2.3B manufacturing campus
Bristol Myers Squibb’s $2.3 billion Houston manufacturing campus is part of the company’s larger $40 billion investment designed to bolster American innovation and manufacturing.
biospace · 3d ago
Replimune rebounds to win FDA approval of melanoma drug
The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.
biopharma_dive · 7d ago
Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
Replimune’s immunotherapy for advanced melanoma faced a perilous regulatory road with two previous rejections, but the drug—to be marketed as Tudriqev—prevailed with strong support from oncologists…
biospace · 7d ago
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
The U.S. Food and Drug Administration today granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy for the treatment of advanced,…
fda_press · 7d ago
No deal between AstraZeneca and BMS, senior source insists: Reuters
Reuters has deflated rumors that AstraZeneca and Bristol Myers Squibb are discussing a possible merger, letting the air out of industry-wide speculation over what could have been the largest deal i…
biospace · 8d ago
Chaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad
The FDA has been trying to mend fences with rare disease drug developers and patient groups since the departure of former Commissioner Marty Makary three months ago. But advisory committee meetings…
biospace · 8d ago
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
The industry has been abuzz since the weekend when talks of a potential mega-merger between Bristol Myers Squibb and AstraZeneca were reported. Meanwhile, Pfizer, Merck and others release second qu…
biospace · 8d ago
As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
While both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be mo…
biospace · 9d ago
An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.
In fact, the former lost tens of billions of dollars in market value following reports of a potential tie-up between the pharmaceutical giants.
biopharma_dive · 10d ago
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
If AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.
biospace · 10d ago

view all news mentions →

brand

OPDIVO QVANTIG

trade names

Nivolumab bms, Nivolumab component of bms-986213, Nivolumab component of opdualag, Opdivo

generic

NIVOLUMAB

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 9m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

OPDIVO QVANTIG

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying OPDIVO QVANTIG

News(10)

Report a data issue

comments(0)

OPDIVO QVANTIG

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying OPDIVO QVANTIG

News(10)

Report a data issue

comments(0)